MorphoSys AG buy t66wv33c
Summary
This prediction ended on 09.04.15 with a price of €57.94. The price of MorphoSys AG has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -21.19%. t66wv33c has 50% into this predictionMorphoSys is a German biopharmaceutical company that develops innovative therapies for the treatment of cancer, autoimmune diseases, and other serious illnesses. The company specializes in developing monoclonal antibodies, which are highly specific and targeted therapies that recognize and bind to specific cancer cells or disease-causing proteins in the body. MorphoSys has a diverse pipeline of products in various stages of development, including several drugs that have shown promising results in clinical trials. The company is listed on the Frankfurt and NASDAQ stock exchanges and has a market capitalization of over $4 billion.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| MorphoSys AG | -2.232% | -2.232% | 195.990% | -5.247% |
| iShares Core DAX® | -0.205% | 2.949% | 17.330% | 18.203% |
| iShares Nasdaq 100 | 1.613% | 5.877% | 37.451% | 56.281% |
| iShares Nikkei 225® | -0.740% | -1.256% | 11.847% | 5.531% |
| iShares S&P 500 | 0.267% | 3.240% | 29.308% | 46.371% |
Comments by t66wv33c for this prediction
In the thread Morphosys AG diskutieren
Kurs könnte hier nach oben drehen
Schlussquartal besser als angenommen und die Verluste kleiner als befürchtet. Langfristig gute Kurssteigerungen möglich.